Good to see the search for improved CLL treatments continues:
1) A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
This is a study evaluating the efficacy, safety, and pharmacodynamics of GS-9973 in subjects with chronic lymphocytic leukemia (CLL), etc.
See also Dr Jeff Sharman's post about this trial at:
2) Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (includes CLL and SLL)
Purpose: To determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab